Tags

Type your tag names separated by a space and hit enter

Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype.
J Breast Cancer. 2016 Jun; 19(2):112-21.JB

Abstract

PURPOSE

Asian-American women have equal or better breast cancer survival rates than non-Hispanic white women, but many studies use the aggregate term "Asian/Pacific Islander" (API) or consider breast cancer as a single disease. The purpose of this study was to assess the risk of mortality in seven subgroups of Asian-Americans expressing the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) tumor marker subtypes and determine whether the risk of mortality for the aggregate API category is reflective of the risk in all Asian ethnicities.

METHODS

The study included data for 110,120 Asian and white women with stage 1 to 4 first primary invasive breast cancer from the California Cancer Registry. The Asian ethnicities identified were Pacific Islander, Southeast Asian (SEA), Indian Subcontinent, Chinese, Japanese, Filipino, and Korean. A Cox regression analysis was used to compute the risk of breast cancer-specific mortality in seven Asian ethnicities and the combined API category versus white women within each of the ER/PR/HER2 subtypes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed.

RESULTS

For the ER+/PR+/HER2- subtype, the combined API category showed a 17% (HR, 0.83; 95% CI, 0.76-0.91) lower mortality risk. This was true only for SEA (HR, 0.75; 95% CI, 0.61-0.91) and Japanese women (HR, 0.60; 95% CI, 0.45-0.81). In the ER+/PR-/HER2- subtype, SEA (HR, 0.57; 95% CI, 0.38-0.84) and Filipino women (HR, 0.71; 95% CI, 0.51-0.97) had a lower risk of mortality. Japanese (HR, 0.49; 95% CI, 0.25-0.99) and Filipino women (HR, 0.74; 95% CI, 0.58-0.94) had a lower HR for the ER-/PR-/HER2+ subtype. For triple-positive, ER+/PR+/HER2+ (HR, 0.84; 95% CI, 0.71-0.98) and triple-negative, ER-/PR-/HER2- (HR, 0.84; 95% CI, 0.74-0.94) subtypes, only the API category showed a lower risk of mortality.

CONCLUSION

Breast cancer-specific mortality among Asian-American women varies according to their specific Asian ethnicity and breast cancer subtype.

Authors+Show Affiliations

Sutter Institute for Medical Research, Sacramento, USA.Sutter Institute for Medical Research, Sacramento, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27382386

Citation

Parise, Carol, and Vincent Caggiano. "Breast Cancer Mortality Among Asian-American Women in California: Variation According to Ethnicity and Tumor Subtype." Journal of Breast Cancer, vol. 19, no. 2, 2016, pp. 112-21.
Parise C, Caggiano V. Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype. J Breast Cancer. 2016;19(2):112-21.
Parise, C., & Caggiano, V. (2016). Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype. Journal of Breast Cancer, 19(2), 112-21. https://doi.org/10.4048/jbc.2016.19.2.112
Parise C, Caggiano V. Breast Cancer Mortality Among Asian-American Women in California: Variation According to Ethnicity and Tumor Subtype. J Breast Cancer. 2016;19(2):112-21. PubMed PMID: 27382386.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype. AU - Parise,Carol, AU - Caggiano,Vincent, Y1 - 2016/06/24/ PY - 2016/02/17/received PY - 2016/05/30/accepted PY - 2016/7/7/entrez PY - 2016/7/7/pubmed PY - 2016/7/7/medline KW - Asian Americans KW - Breast neoplasms KW - Healthcare disparities KW - Mortality SP - 112 EP - 21 JF - Journal of breast cancer JO - J Breast Cancer VL - 19 IS - 2 N2 - PURPOSE: Asian-American women have equal or better breast cancer survival rates than non-Hispanic white women, but many studies use the aggregate term "Asian/Pacific Islander" (API) or consider breast cancer as a single disease. The purpose of this study was to assess the risk of mortality in seven subgroups of Asian-Americans expressing the estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2) tumor marker subtypes and determine whether the risk of mortality for the aggregate API category is reflective of the risk in all Asian ethnicities. METHODS: The study included data for 110,120 Asian and white women with stage 1 to 4 first primary invasive breast cancer from the California Cancer Registry. The Asian ethnicities identified were Pacific Islander, Southeast Asian (SEA), Indian Subcontinent, Chinese, Japanese, Filipino, and Korean. A Cox regression analysis was used to compute the risk of breast cancer-specific mortality in seven Asian ethnicities and the combined API category versus white women within each of the ER/PR/HER2 subtypes. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed. RESULTS: For the ER+/PR+/HER2- subtype, the combined API category showed a 17% (HR, 0.83; 95% CI, 0.76-0.91) lower mortality risk. This was true only for SEA (HR, 0.75; 95% CI, 0.61-0.91) and Japanese women (HR, 0.60; 95% CI, 0.45-0.81). In the ER+/PR-/HER2- subtype, SEA (HR, 0.57; 95% CI, 0.38-0.84) and Filipino women (HR, 0.71; 95% CI, 0.51-0.97) had a lower risk of mortality. Japanese (HR, 0.49; 95% CI, 0.25-0.99) and Filipino women (HR, 0.74; 95% CI, 0.58-0.94) had a lower HR for the ER-/PR-/HER2+ subtype. For triple-positive, ER+/PR+/HER2+ (HR, 0.84; 95% CI, 0.71-0.98) and triple-negative, ER-/PR-/HER2- (HR, 0.84; 95% CI, 0.74-0.94) subtypes, only the API category showed a lower risk of mortality. CONCLUSION: Breast cancer-specific mortality among Asian-American women varies according to their specific Asian ethnicity and breast cancer subtype. SN - 1738-6756 UR - https://www.unboundmedicine.com/medline/citation/27382386/Breast_Cancer_Mortality_among_Asian_American_Women_in_California:_Variation_according_to_Ethnicity_and_Tumor_Subtype_ L2 - https://ejbc.kr/DOIx.php?id=10.4048/jbc.2016.19.2.112 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.